# Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

> **NCT02137772** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 570 (actual)

## Conditions studied

- Prevention of CMV Infection or Disease

## Interventions

- **DRUG:** Letermovir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02137772
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-06
- **Primary completion:** 2016-08-08
- **Final completion:** 2016-11-21
- **Target enrollment:** 570 (ACTUAL)
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02137772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02137772, "Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02137772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*